Service d'Urologie Centre Hospitalier Auxerre, France, UK.
BJU Int. 2010 Jan;105(1):49-56. doi: 10.1111/j.1464-410X.2009.08716.x.
To calculate the total cost per patient of prostate cancer treatment and the economic cost burden by stage, in the first year after diagnosis, for five European countries.
Data from the Information Management Systems, Inc. database, survival data, expert opinion, published data and unit costs from various published official sources were used to calculate total costs per patient by stage for each country, from a payer's perspective. Diagnostic costs, first surgery, radio-, chemo- and hormonal therapy costs were included. Costs were aggregated for incident cases.
The mean direct costs per patient for initial treatment were euro3698 in Germany, euro3256 in Spain, euro3682 in the UK, euro5226 in Italy and euro5851 in France. The total costs for all diagnosed patients in the first year from diagnosis were (million euro) 116.7 (UK), 244 (Germany), 385 (France), 202 (Italy) and 114.6 (Spain).
The direct initial healthcare cost burden of the most common non-skin-related male cancer, prostate cancer, in France, Germany, Italy, Spain and the UK is considerable. Given the high and increasing prevalence of prostate cancer due to ageing populations in Europe, and the significant cost burden of the disease, national health policy makers should be aware of prostate cancer as a priority disease area.
计算前列腺癌患者在诊断后第一年的每个阶段的总治疗费用和经济成本负担，涉及五个欧洲国家。
使用来自 Information Management Systems, Inc. 数据库的数据、生存数据、专家意见、已发表数据以及各种已发布官方来源的单位成本，从支付者的角度计算每个国家每个阶段的每位患者的总费用。包括诊断费用、首次手术、放疗、化疗和激素治疗费用。对新发病例进行成本汇总。
德国初始治疗每位患者的平均直接费用为 3698 欧元，西班牙为 3256 欧元，英国为 3682 欧元，意大利为 5226 欧元，法国为 5851 欧元。诊断后第一年所有确诊患者的总费用（百万欧元）分别为：英国 116.7（欧元）、德国 244（欧元）、法国 385（欧元）、意大利 202（欧元）和西班牙 114.6（欧元）。
在法国、德国、意大利、西班牙和英国，前列腺癌这种最常见的非皮肤相关男性癌症的直接初始医疗保健成本负担相当大。鉴于欧洲人口老龄化导致前列腺癌的高发率和疾病的巨大成本负担，国家卫生政策制定者应将前列腺癌视为优先疾病领域。
